Meta Information
ID:fisetin-liposomal
Name:Liposomal Fisetin
Schema Version:1.5
Alternate Names
- Liposomal 3,3',4',7-tetrahydroxyflavone
Active Compound
fisetin
Intervention Type
therapeutic_agent
Delivery
Route:
oral
Scope:
- systemic
Regulatory Status
- us:dietary_supplement
Indication
Focus:
healthspan
Description:
Targeting cellular senescence to potentially reduce age-related inflammation and improve tissue function.
Typical Protocol
- Take 100-500 mg daily for 2-3 consecutive days.
- Repeat this short 'hit-and-run' cycle once per month or as clinically guided.
Expected Cost Mean
Low Cost:
30
High Cost:
70
Cost Type:
monthly
Description:
Cost for a monthly intermittent cycle; not covered by insurance.
Summary
Fisetin is a plant-derived flavonoid investigated for its senolytic properties—the ability to selectively clear dysfunctional, senescent cells. These 'zombie' cells accumulate with age and contribute to chronic inflammation. The liposomal formulation encapsulates fisetin in lipids to significantly enhance its poor natural bioavailability, aiming for more effective systemic delivery and cellular uptake.
Purpose
A high-bioavailability senolytic agent to clear senescent cells.
Card Summary
A high-bioavailability form of a natural senolytic compound used to clear aged 'zombie' cells.
Drug Class
Drugs In Class
Empty Array
Impact
Score:
4.5
Justification:
Potent senolytic mechanism with strong animal data, but limited human healthspan trial results.
Evidence
Grade:
C
Score:
3.8
Justification:
Robust animal and in-vitro data, but lacks large-scale human RCTs for healthspan.
Safety
Score:
3.5
Justification:
Generally well-tolerated, but long-term safety of high-bioavailability forms is not fully established.
Flags
- Liposomal delivery significantly increases bioavailability; do not use standard fisetin dosages.
- May interact with anticoagulant and antiplatelet drugs (blood thinners).
- Long-term safety of periodic high-dose senolytic therapy in humans is unknown.
- Quality and dosage can vary significantly between supplement manufacturers.
Verdict
A promising experimental senolytic, but human healthspan evidence remains preliminary.
Created
2026-06-12T17:49:47.967764Z
Ai Model
Gemini 2.5 Pro (High)